Heart failure prevention plan for cancer survivors treated with past chemotherapy
Tests a heart care plan in cancer survivors who had chemotherapy years ago.
Plain-language title generated from the registry record
Registry title: Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)
Key facts
- Where
- Melbourne, AustraliaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for cancer survivors who had chemotherapy or chest radiotherapy long ago and do not have heart failure. It tests a plan to lower heart failure risk.
- Age
- 40 to 85 years
- Sex
- All sexes
- Disease stage
- History of cancer more than 10 years ago, with no previous heart failure.
- Earlier treatment
- Must have had potentially toxic cancer treatment: anthracycline (any dose), trastuzumab (Herceptin) for HER2 breast cancer, tyrosine kinase inhibitors (e.g. sunitinib), or left chest radiotherapy.
- Biomarker or test result
- For trastuzumab, breast cancer with the HER2 mutation.
Main reasons for not taking part
- Ejection fraction below 50% on the baseline heart ultrasound
- Previous heart failure (NYHA class above 2)
- Valve narrowing or leaking worse than moderate
- Systolic blood pressure below 110 mmHg
- Cannot take beta blockers or ACE inhibitors, or already takes both an ACE inhibitor/ARB and a beta blocker
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT04962711, who can take part
Where in Australia
- Baker Heart and Diabetes InstituteMelbourne, AustraliaContact: Thomas MarwickTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Baker Heart and Diabetes Institute
- Trial code
- NCT04962711
- Record updated
- 31 May 2025
- Original description
This is a prospective study in which a process of identifying and reducing heart failure (HF) risk will be applied to cancer survivors >55 years old with chemotherapy >5 years ago.Read full original descriptionShow less
Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)
This is a prospective study in which a process of identifying and reducing heart failure (HF) risk will be applied to cancer survivors >55 years old with chemotherapy >5 years ago.
The overall goal of this study to identify the feasibility and value of risk-guided cardiac rehabilitation (exercise, risk factor modification, and behavioural support) as a component of survivorship care.
Inclusion: History of cancer > 10 years ago; Have received potentially toxic chemotherapy Anthracycline (any dose) Trastuzumab (Herceptin) in breast-cancer with the HER2 mutation OR Tyrosine kinase inhibitors (e.g. sunitinib) OR Left chest radiotherapy.
Exclusion: History of previous heart failure (baseline New York Heart Association (NYHA) classification >2); Contraindications to beta blockers or angiotensin-converting enzyme inhibitors; Oncologic (or other) life expectancy <12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial; Already taking both angiotensin converting enzyme inhibitors/angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both; Ejection fraction at baseline echo <50%; Valvular stenosis or regurgitation of >moderate severity; Systolic BP <110 mmHg; Pulse <60/minute if not on beta blocker; Inability to acquire interpretable images (identified from baseline echo); Unable to provide written informed consent to participate in this study.